Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 22, No 16 (August 15), 2004: pp. 3389-3394
© 2004 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2004.09.122

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stockler, M.
Right arrow Articles by Warr, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stockler, M.
Right arrow Articles by Warr, D.

Acetaminophen (Paracetamol) Improves Pain and Well-Being in People With Advanced Cancer Already Receiving a Strong Opioid Regimen: A Randomized, Double-Blind, Placebo-Controlled Cross-Over Trial

Martin Stockler, Janette Vardy, Avinesh Pillai, David Warr

From the Department of Medicine and School of Public Health, and NHMRC Clinical Trials Centre, University of Sydney, Camperdown; Sydney Cancer Centre, Concord Repatriation General Hospital, Concord, Australia; and Princess Margaret Hospital, Toronto, Canada

Address reprint requests to Martin Stockler, MBBS, Sydney Cancer Centre, Royal Prince Alfred Hospital–GH6, Missenden Rd, Camperdown, NSW 2050, Australia; e-mail: stockler{at}med.usyd.edu.au

PURPOSE: To determine whether adding regular acetaminophen (paracetamol) could improve pain and well-being in people with advanced cancer and pain despite strong opioids.

PATIENTS AND METHODS: Participants took acetaminophen for 48 hours and placebo for 48 hours. The order (acetaminophen or placebo first) was randomly allocated. Pain was the primary outcome. Preferences, number of opioid breakthrough doses, overall well-being, nausea and vomiting, drowsiness, constipation, and cold sweats were secondary outcomes. Patients rated themselves daily with visual analog scales (VAS) and a verbal numeric scale (VNS) for pain, all scaled from 0 to 10.

RESULTS: Thirty patients completed the trial. The oral opioid was morphine in 23 patients and hydromorphone in seven patients. The median daily opioid dose in oral morphine equivalents was 200 mg (range, 20 to 2,100 mg). Nonsteroidal anti-inflammatory drugs, corticosteroids, or both were used by 16 patients. Pain and overall well-being were better for patients receiving acetaminophen than for those receiving placebo. The mean difference was 0.4 (95% CI, 0.1 to 0.8; P = .03) in VNS for pain, 0.6 (95% CI, –0.1 to 1.3; P = .09) in VAS for pain, and 0.7 (95% CI, 0.0 to 1.4; P = .05) in VAS for overall well-being. More patients preferred the period they took acetaminophen (n = 14) than the period they took placebo (n = 8), but many had no preference (n = 8). There were no differences in the other outcomes.

CONCLUSION: Acetaminophen improved pain and well-being without major side effects in patients with cancer and persistent pain despite a strong opioid regimen. Its addition is worth considering in all such patients.

Supported by a grant from the Cancer Council, New South Wales, Australia, and Janssen Cilag.

Presented in abstract form at the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31-June 3, 2003; the Medical Oncology Group of Australia Annual Scientific Meeting, Canberra, Australia, August 13-15, 2003; and the Clinical Oncology Society of Australia Annual Scientific Meeting, Perth, Australia, November 26-28, 2003.

Authors' disclosures of potential conflicts of interest are found at the end of this article.




This article has been cited by other articles:


Home page
J Antimicrob ChemotherHome page
L. Pumbwe, C. A. Skilbeck, and H. M. Wexler
Induction of multiple antibiotic resistance in Bacteroides fragilis by benzene and benzene-derived active compounds of commonly used analgesics, antiseptics and cleaning agents
J. Antimicrob. Chemother., December 1, 2007; 60(6): 1288 - 1297.
[Abstract] [Full Text] [PDF]


Home page
JAOA: Journal of the American Osteopathic AssociationHome page
G. H. Pharo and L. Zhou
Controlling Cancer Pain With Pharmacotherapy
J Am Osteopath Assoc, December 1, 2007; 107(suppl_7): ES22 - ES32.
[Abstract] [Full Text] [PDF]


Home page
JAOA: Journal of the American Osteopathic AssociationHome page
G. H. Pharo and L. Zhou
Pharmacologic Management of Cancer Pain
J Am Osteopath Assoc, November 1, 2005; 105(suppl_5): S21 - S28.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. Hardy, E. Reymond, and M. Charles
Acetaminophen in Cancer Pain
J. Clin. Oncol., March 1, 2005; 23(7): 1586 - 1586.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2004 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online